Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

July 25, 2018

Study Completion Date

July 25, 2018

Conditions
Tumor Lysis Syndrome
Interventions
DRUG

Febuxostat

Intervention is orally administered to patients in this arm.

Trial Locations (17)

1083

Semmelweis Egyetem (paediatric), Budapest

1085

Semmelweis Egyetem, Budapest

1527

University Hospital Tsaritsa Yoanna, Sofia

4032

Debreceni Egyetem Klinikai Központ, Debrecen

10002

Hospital de San Pedro de Alcantara, Cáceres

10126

Ospedale Infantile Regina Margherita, Torino

16147

Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova

28007

Hospital General Universitario Gregorio Maranon, Madrid

28046

Hospital Universitario La Paz, Madrid

33081

SOC Oncologia Medica A - Centro di Riferimento Oncologico, Aviano

37126

Azienda Ospedaliera Universitaria Integrata di Verona, Verona

40138

Policlinico S. Orsola Malpighi, Bologna

46026

Hospital Universitari i Politècnic La Fe, Valencia

50134

A.O.U.C. Azienda Ospedaliero - Universitaria Careggi, Florence

50139

Azienda Ospedaliero Universitaria Meyer, Florence

56126

Azienda Ospedaliero-Universitaria Pisana, Pisa

00165

IRCCS Ospedale Pediatrico Bambino Gesù, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Menarini Group

INDUSTRY

NCT03605212 - Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults | Biotech Hunter | Biotech Hunter